Attached files
| file | filename |
|---|---|
| EX-10.1 - EXHIBIT A OF THE MILESTONE INVESTMENT AGREEMENT - GENETHERA INC | exhibit_10-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): November 30,
2018
GENETHERA, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-27237
|
65-0622463
|
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
|
6860 Broadway, Denver, CO
|
80221
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (303) 955-0190
|
|
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing
obligation of the registrant under any of the following
provisions.
|
|
|
|
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
|
|
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
|
|
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR
240.14d-2(b))
|
|
|
|
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
1
Item 1.01 Entry into a Material Definitive
Agreement.
GENETHERA INC.
COMPLETES THIRD MILESTONE OF THEIR “MILESTONE INVESTMENT
AGREEMENT” WITH FOGT, LLC
On
November 30th 2018, GeneThera
Inc. completed the third milestone as described in Exhibit A of the
Milestone Investment Agreement. The Completion of this milestone
enables the Company to receive a payment of $1,200,000 under the
Terms of the Agreement.
Item 9.01 Financial Statements and
Exhibits.
|
Exhibit
Number
|
Description
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this Current Report on Form 8-K to be signed on its
behalf by the undersigned hereunto duly authorized.
|
|
GeneThera,
Inc.,
a Nevada
Corporation
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Antonio
Milici
|
|
|
|
|
Antonio Milici,
CEO
|
|
Date: December 4, 2018
2